Impaired vascular function and repair in patients with premature coronary artery disease by Brittan, M. et al.
EU RO PEAN
SOCIETY O F
CARDIOLOGY ®Original scientific paper
Impaired vascular function and repair
in patients with premature coronary
artery disease
Mairi Brittan1,2, Amanda Hunter1, Mounia Boulberdaa3,
Takeshi Fujisawa1,2, Elizabeth M Skinner1,2, Anoop SV Shah1,
Andrew H Baker3 and Nicholas L Mills1
Abstract
Background: Endothelial dysfunction is central to the pathogenesis of coronary artery disease, but the role of local and
circulating endothelial progenitor cells in maintaining vascular health is poorly understood. We hypothesised that
impaired local and circulating vascular repair mechanisms predispose to endothelial dysfunction and the premature
onset of coronary artery disease.
Methods and results: Patients with premature coronary artery disease (n¼ 16) and healthy age- and sex-matched
controls (n¼ 16) underwent venous occlusion plethysmography with intra-arterial infusion of acetylcholine and sodium
nitroprusside. Numbers of circulating endothelial progenitor cells were directly quantified in whole blood by flow
cytometry. Endothelial cells were isolated from the blood vessel wall and from peripheral blood mononuclear cells,
and expanded in vitro for phenotypic and functional characterisation and analysis of microRNA expression levels. A
dose-dependent increase in forearm blood flow (p< 0.001) was attenuated in response to the endothelial-dependent
vasodilator acetylcholine in patients compared with controls (p¼ 0.03). No differences in the number of circulating
endothelial progenitor cells or in the phenotype, function or microRNA expression levels of endothelial outgrowth cells
isolated from blood were observed in patients and controls. Conversely, local vessel wall endothelial cells from patients
had significant impairments in proliferation, adhesion and migration, and significantly reduced expression levels of
microRNAs known to regulate endothelial function (miRs 10 a, let7b, 126 and 181 b) (p< 0.05 for all).
Conclusion: Local vessel wall derived endothelial cells, rather than circulating endothelial progenitor cells and their
progeny, are impaired in patients with vascular dysfunction and premature coronary artery disease.
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Translational perspective
Endothelial progenitor cells (EPCs) hold great thera-
peutic potential for vascular regeneration, although
their origin, whether the bone marrow or blood vessel
wall, remains unclear. In order to exploit the full poten-
tial of EPCs, it is vital that the cell-speciﬁc mechanisms
that contribute to the pathophysiology of coronary
artery disease are fully understood. Our observation
that vessel wall endothelial cells are broadly dysregu-
lated in patients with premature coronary artery disease
whereas circulating EPCs are functionally normal,
highlights important diﬀerences in endothelial cells
from diﬀerent locations. Future studies of vessel wall
endothelial cells are likely to advance our understand-
ing of the mechanisms of premature coronary artery
1BHF/University Centre for Cardiovascular Science, University of
Edinburgh, UK
2Scottish Centre for Regenerative Medicine, University of Edinburgh, UK
3Institute of Cardiovascular and Medical Sciences, BHF Glasgow
Cardiovascular Research Centre, University of Glasgow, UK
Corresponding author:
Mairi Brittan, BHF/University Centre for Cardiovascular Science, Scottish
Centre for Regenerative Medicine, 5 Little France Drive, Edinburgh,
EH16 4UU, UK.
Email: mbrittan@staffmail.ed.ac.uk
European Journal of Preventive
Cardiology
2015, Vol. 22(12) 1557–1566
! The European Society of
Cardiology 2014
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2047487315600169
ejpc.sagepub.com
 at Glasgow University Library on June 13, 2016cpr.sagepub.comDownloaded from 
disease and may lead to novel approaches to enhance
vascular repair.
Introduction
Atherosclerosis occurs as a result of recurrent injury to
the vasculature throughout life, with many risk factors
known to play a role in the development, progression
and clinical consequences of disease.1,2 Our under-
standing of the cellular mechanisms that underpin cor-
onary artery disease is incomplete. Recent interest in
vascular repair and regeneration has gathered momen-
tum, as deﬁciencies in these mechanisms have been
implicated in the pathogenesis of atherosclerosis.3
Postnatal blood vessel growth and repair was trad-
itionally thought to occur exclusively from the migra-
tion and proliferation of endothelial cells within
existing mature blood vessels.4 In 1997, CD34þEPCs
in the adult circulation were reported to promote thera-
peutic angiogenesis in experimental ischaemia.5 It is
now accepted that early reports of adult EPCs refer
to pro-angiogenic cells of haematopoietic origin.6 As
such, a large body of research is dedicated to delinea-
tion of the origin, phenotype, function and transla-
tional aspects of a true adult human EPC.7 EPCs are
most commonly studied by direct enumeration in per-
ipheral blood by ﬂow cytometry as
CD34þCD133þKDRþ cells.8 Colony forming
assays following ex vivo culture of peripheral blood
mononuclear cells (MNCs) are also widely used for
studies of EPCs. Late endothelial outgrowth cells
(EOCs) lack expression of haematopoietic and leuko-
cyte markers, demonstrate hierarchical proliferative
potential and can form de novo blood vessels
in vivo.9–12 Therefore, EOCs appear to arise from
true circulating EPCs.
Functional heterogeneity has been demonstrated in
endothelial cells from diﬀerent vascular locations, and
appears to persist upon removing them from their micro-
environment for in vitro analyses.13–16 Therefore it is
important to study organ-appropriate endothelial cells,
although in humans such studies are limited due to prob-
lems with accessibility. Reduced numbers of circulating
EPCs have been reported in patients with coronary
artery disease.17–24 However, these data are confounded
by discrepancies in the phenotypic deﬁnitions of EPC
with overlap between haematopoietic stem cells and
other circulating lineages.9 Moreover, most studies
have failed to conﬁrm that their reported putative
EPCs are bona ﬁde progenitor cells, that is, via isolation
for in vitro expansion and functional assessment.
We hypothesised that impaired local and circulating
vascular repair mechanisms predispose to endothelial
dysfunction and the premature onset of coronary
artery disease. Here, we have used a broad range of
quantitative and functional experiments to assess
morphology, growth kinetics, phenotype, function
and microRNA expression levels in endothelial cells
derived from the vessel wall and from circulating mono-
nuclear cells in patients with premature coronary artery
disease and age- and sex-matched healthy control sub-
jects. We demonstrate that signiﬁcant functional
impairments and reduced expression levels of
microRNAs known to regulate endothelial cell function
are speciﬁc to local vessel wall endothelial cells in
patients with premature coronary artery disease.
Conversely, we observed no diﬀerences in the number
of circulating EPCs, or in the function and microRNA
expression by late outgrowth EOCs isolated from the
same patients compared with healthy subjects.
Methods
Detailed description of the materials and methods are
available in the Supplementary Material online.
Subjects
The study was performed with the approval of the
South East Scotland Research Ethics Committee, in
accordance with the Declaration of Helsinki and with
the written informed consent of all participants.
Patients with premature coronary artery disease and a
family history of premature coronary artery disease
(n¼ 16) were identiﬁed from the outpatient depart-
ment, Royal Inﬁrmary of Edinburgh, Scotland, UK.
A control group of healthy age- and sex-matched sub-
jects (n¼ 16) with no evidence of signiﬁcant coronary
artery disease following computed tomography coron-
ary angiography (CTCA) was recruited from the
Clinical Research Imaging Centre, Royal Inﬁrmary of
Edinburgh.
Tissue sampling and vascular assessment
Subjects attended the Clinical Research Facility at the
Royal Inﬁrmary of Edinburgh for vascular assessment
and tissue sampling; peripheral blood was collected for
direct quantiﬁcation of endothelial progenitor popula-
tions by ﬂow cytometry, and for the isolation and
in vitro expansion of circulating EPCs to generate
endothelial outgrowth cells. Vessel wall endothelial
cells were isolated by wire biopsy for in vitro expansion.
In vitro assessment and microRNA studies
Vessel wall endothelial cells and endothelial outgrowth
cells from patients and controls underwent morpho-
logical and phenotypic assessment by ﬂow cytometry
and immunocytochemistry. Functional assessment of
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growth kinetics, adhesion and migration, and
microRNA extraction and TaqMan qPCR analysis
was also carried out in these cells.
Statistical analyses
Plethysmographic data were analysed as described pre-
viously.25 Forearm blood ﬂow (FBF) was analysed
using two-way repeated measures analysis of variance.
Continuous variables are reported as mean and stand-
ard error of the mean (SEM) or median (interquartile
range (IQR)). Summary statistics were compared by
Chi-squared, Fisher’s exact, Student’s t- and Mann–
Whitney U tests where appropriate. Statistical signiﬁ-
cance was taken at p< 0.05. Statistical analyses were
performed with GraphPad Prism (version 6,
GraphPad Software Inc., CA, USA).
Results
Patients with premature coronary artery disease and
controls were matched for age and sex (Table 1).
Endothelial-dependent and -independent
vasodilatation
FBF was measured using venous occlusion plethysmo-
graphy before and during intra-arterial infusions of
endothelial-dependent (acetylcholine) and -independent
(sodium nitroprusside) vasodilators. There was a dose-
dependent increase in FBF with both vasodilators
(p< 0.001). Vasodilatation was reduced in response to
acetylcholine in patients compared with controls (peak
FBF: 5.1 0.9 vs. 9.3 2.7ml/100ml of tissue per min,
p¼ 0.03), but was similar in response to sodium nitro-
prusside (p¼ 0.37) (Figure 1).
Circulating EPCs
Circulating EPCs (CD34þCD133þKDRþ) and other
progenitor subpopulations (CD34þ, CD34þCD45,
CD34þKDRþ, CD34þCD133þ, CD133þ and
CD133þKDRþ) were directly quantiﬁed in whole
blood using ﬂow cytometry to ascertain diﬀerences
between patients and control subjects. No diﬀerences
were observed in the number of any circulating subpo-
pulation between patients and controls (Table 2; Figure
S1 in the Supplementary Material online).
Efficiency of cell isolation and growth kinetics
Growth kinetics of outgrowth from vessel wall endo-
thelial cells and peripheral blood MNCs, that is, late
outgrowth EOCs, were calculated to identify functional
diﬀerences between these cells in patients and controls.
Outgrowth was observed as colonies that were
expanded to form cobblestone monolayers with typical
endothelial morphology, which were maintained in cul-
ture up to passage 10 (Figure 2(a) to (c) and (i) to (k)).
For vessel wall endothelial cells, colony outgrowth was
observed from 14/16 patients (88%) and 15/16 controls
(94%), and no diﬀerences were observed between
patients and controls in the day of ﬁrst colony appear-
ance (9.1 1.1 vs. 7.4 1.2 days, p¼ 0.30) or the total
number of colonies (10.8 3.3 vs. 9.4 2.5, p¼ 0.92)
(Figure 2(e) and (f)). For late outgrowth EOCs, colo-
nies were derived from all subjects with colonies emer-
ging slightly later from patients compared with controls
(10.3 0.8 vs. 7.9 0.5 days, p¼ 0.03), but with no dif-
ference in the number of colonies obtained from
patients compared with controls (11.8 2.3 vs.
20.9 17.7 colonies, p¼ 0.06) (Figure 2(m) and (n)).
Mean population doubling time (PDT) between pas-
sages 2 and 8 by vessel wall endothelial cells from
patients was signiﬁcantly reduced compared with con-
trols (mean PDT SEM: 2.3 0.2 vs. 3.4 0.5,
p¼ 0.02) (Figure 2(g)). No signiﬁcant diﬀerence was
observed in mean PDT between passages 2 and 8 by
late outgrowth EOCs from patients compared with con-
trols (2.2 0.2 vs. 2.3 0.2, p¼ 0.89) (Figure 2(o)).
Similarly, cumulative population doubling levels
(CPDLs) of vessel wall endothelial cells from patients
were signiﬁcantly reduced compared with controls
(CPDL at passage 8: 18.1 1.4 vs. 23.6 1.4,
p¼ 0.03) (Figure 2(h)). No signiﬁcant diﬀerence was
observed in CPDL by late outgrowth EOCs from
patients compared with controls (22.3 0.7 vs.
22.2 1.4, p¼ 0.94) (Figure 2(p)).
Phenotypic characterisation of cells
Vessel wall endothelial cells and late outgrowth EOCs
from patients and controls had similar ubiquitous
expression of von Willebrand factor (vWF)
(Figure 2(d) and (l)). Vessel wall endothelial cells main-
tained a high expression of mature endothelial cell mar-
kers with no diﬀerences between patients and controls
at early (2–4) passages (CD31þ 98.3 0.6% vs. 96.2
1.4%, p¼ 0.24; CD146þ 98.5 0.5% vs. 97.5 0.9%,
p¼ 0.15) and late (5–10) passages (CD31þ 97.5 0.6%
vs. 97.9 1.2%, p¼ 0.14; CD146þ 95.6 1.3% vs.
92.9 3.9%, p¼ 0.89). A relatively high expression of
KDR by vessel wall endothelial cells was maintained
during culture in patients (89.17Ye haematopoietic
antigen, CD45, was expressed at low levels throughout
(4% for all) (Figure S2 and Table S1 online).
There was no diﬀerence in the phenotype of late out-
growth EOCs between patients and controls at early
(2–4) passages (CD31þ 96.5 1.0% vs. 92.0 2.9%,
p¼ 0.40; CD146þ 96.6 1.1% vs. 97.4 1.1%,
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p¼ 0.26), and late (5–10) passages (CD31þ 94.0
2.5% vs. 96.4 1.4%, p¼ 0.90; CD146þ 98.8 0.3%
vs. 98.3 0.7%, p¼ 0.80). Expression of KDR by late
outgrowth EOCs was similar in early and late passages
in patients (71.9 10.1% to 73.8 10.8%, p¼ 0.45)
and controls (70.0 9.1% to 60.1 10.6%, p¼ 0.47),
and did not change signiﬁcantly in patients compared
with controls at late passage (p¼ 0.14). CD45 expres-
sion was low throughout (4% for all) (Figure S2 and
Table S1 online).
Functional characterisation of cells
In order to identify cell-speciﬁc mechanisms that may
be dysfunctional and thus contribute to the
pathophysiology of premature coronary artery disease,
we carried out in vitro functional assessments of migra-
tion and adhesion. Vessel wall endothelial cells from
patients had reduced migration in a wound-healing
assay compared with controls (wound coverage
at 24 h: 35.9 8.8% vs. 64.8 12.7%, p¼ 0.04)
(Figure 3(a) to (c)). Migration was similar for late out-
growth EOCs in patients and controls (62.2 8.2% vs.
56.3 8.0%, p¼ 0.60) (Figure 3(e) to (g)). Cell adhe-
sion was reduced in vessel wall endothelial cells from
patients compared with controls (adherent cells per
well: 31.5 5.4 vs. 53.3 6.6, p¼ 0.02) (Figure 3(d)),
but there were no diﬀerences in adhesion by late out-
growth EOCs (52.0 7.1 vs. 57.3 11.2, p¼ 0.83)
(Figure 3(h)).
Table 1. Characteristics of patients with premature coronary artery disease and controls.
Patients Controls p value
Age 51 5 50 6 0.81
Sex, male 15/16 (94%) 15/16 (94%) 0.99
Past medical history
Myocardial infarction 11 (69%) 0 (0%) <0.001
Angina 16 (100%) 0 (0%) <0.001
PCI 15 (94%) 0 (0%) <0.001
CABG 2 (13%) 0 (0%) 0.48
Risk factors
Current smokers 0 (0%) 0 (0%) 0.99
Hypertension 5 (31%) 1 (6%) 0.66
Hyperlipidaemia 7 (44%) 2 (13%) 0.78
Hemodynamic variables
Systolic blood pressure, mmHg 144.9 14.6 135.3 16.6 0.10
Diastolic blood pressure, mmHg 88.5 11 83.4 10.4 0.19
Heart rate, beats/min 56.9 8.3 62.7 8.9 0.07
Total cholesterol, mg/dl 88 27 95 18 0.40
LDL cholesterol, mg/dl 56 23 58 18 0.81
Glucose (random), mg/dl 90 11 85 7 0.12
Drug treatment
Aspirin 16 (100%) 0 (0%) <0.001
Clopidogrel 6 (38%) 0 (0%) 0.02
Beta blocker 9 (56%) 0 (0%) <0.001
ACE inhibitor/ARB 14 (88%) 0 (0%) <0.001
Calcium channel blocker 2 (13%) 0 (0%) 0.48
Nitrate 3 (19%) 0 (0%) 0.23
Statin 16 (100 %) 0 (0%) <0.001
Coronary artery disease
Age at first coronary event 47 2 N/A –
Single-vessel disease 2 (13%) 1 (6%) 0.99
Two-vessel disease 6 (38%) 0 (0%) 0.02
Three-vessel disease 8 (50%) 0 (0%) 0.002
PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; LDL: low-density lipoprotein; ACE: angiotensin-converting enzyme;
ARB: angiotensin receptor blocker.
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MicroRNA expression by local vessel wall endothelial
cells and circulating EOCs
MicroRNA (miR) expression is often selective or
enriched in individual cell types and cell speciﬁc ‘miR
signatures’ can deﬁne cellular function. We assessed
expression levels of miRs 10 a, 27 b, let7b, 126
and 181 b in early passage local vessel wall endothelial
cells and late outgrowth EOCs from patients and con-
trols (n¼ 8 for each). Levels of miR10 a (0.7 0.1 vs.
1.0 0.1, p¼ 0.007), let7b (0.64 0.1 vs. 1 0.1,
p¼ 0.0004), 126 (0.69 0.1 vs. 1.0 0.1, p¼ 0.02)
and 181 b (0.69 0.1 vs. 1.0 0.1, p¼ 0.02) were sig-
niﬁcantly reduced in vessel wall endothelial cells from
patients compared with controls (Figure 4). No diﬀer-
ences in miR expression levels were observed in late
outgrowth EOCs from patients and controls (p> 0.05
for all) (Figure 4).
Discussion
The role of local and circulating EPCs in maintaining
vascular health is not well understood, with deﬁciencies
in vascular repair potentially contributing to endothe-
lial dysfunction and the development of premature cor-
onary artery disease. We compared numbers of
circulating EPCs in patients with premature coronary
artery disease and matched controls, and additionally
compared endothelial outgrowth following in vitro
expansion of peripheral blood MNCs and endothelial
cells isolated and expanded from the local blood vessel
wall. Whilst patients had endothelial-dependent vaso-
motor dysfunction compared with controls we found
no diﬀerences in the number of circulating EPCs or in
the function of late outgrowth EOCs isolated from cir-
culating progenitor cells. In contrast, endothelial cells
isolated directly from the vessel wall had marked
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Figure 1. Endothelial-dependent and -independent vasodilatation in patients with premature coronary artery disease and matched
controls. Both vasodilators caused a dose-dependent increase in forearm blood flow (FBF) in the infused arm (p< 0.001), but
vasodilatation was reduced in response to infusion of the endothelial-dependent vasodilator acetylcholine in patients (red) compared
with controls (blue, peak FBF: 5.1 0.9 vs. 9.3 2.7ml/100ml tissue per min, p¼ 0.03). Vasodilatation was similar in response to
infusion of the endothelial-independent vasodilator sodium nitroprusside (SNP) in patients and controls (p¼ 0.37, n¼ 16 for both).
Closed circle: infused FBF; open circle: non-infused FBF.
Table 2. Circulating subpopulations of progenitor cells.
Number of circulating progenitor cells ( 106/l)
p value
Patients (n¼ 16) Controls (n¼ 16)
CD34þCD133þKDRþ 0.8 (0.4–2.8) 0.7 (0.2–1.1) 0.41
CD34þ 149.3 (35.5–235.0) 99.4 (28.4–262.1) 0.68
CD34þCD45 20.1(7.6–34.7) 18.3 (5.5–25.0) 0.50
CD34þKDRþ 5.6 (3.0–43.8) 5.9(2.1–15.1) 0.62
CD34þCD133þ 5.4 (2.8–12.8) 5.2 (3.0–7.6) 0.49
CD133þ 9.5 (5.2–17.0) 13.0 (4.0–18.1) 0.80
CD133þKDRþ 2.7 (1.0–5.2) 1.6 (1.0–3.5) 0.66
Data are median (interquartile range) expressed as an absolute cell count ( 106/l).
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impairment in proliferation, adhesion and migration,
and reduced levels of expression of miRs known to
regulate endothelial function in patients compared
with controls. These ﬁndings suggest that impairment
of local vessel wall endothelial cells, rather than
circulating EPCs, contributes to endothelial dysfunc-
tion in patients with premature coronary artery disease.
Previous observations suggest that patients with car-
diovascular disease have reduced numbers of circulat-
ing EPCs.17–24,26 However, we observed no diﬀerences
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Figure 2. Morphology and growth kinetics of vessel wall derived endothelial cells and endothelial outgrowth from circulating cells.
Colonies were derived with a high efficiency from vessel wall endothelial cells (ECs) ((a) to (c), 10 magnification) and from peripheral
blood mononuclear cells ((i) to (k), 10 magnification) in patients and controls. Cell outgrowth from both sources was morpho-
logically analogous with typical endothelial ‘cobblestone’ morphology. Representative images of the emergence and expansion of
colonies from a patient with premature coronary artery disease are shown. Vessel wall endothelial cells (d) and endothelial outgrowth
cells (EOCs) (l) from patients and controls had ubiquitous expression of von Willebrand factor (vWF; red cytoplasmic staining; DAPI,
blue nuclear staining. Images shown are from a control subject at passage 3, scale bars 50mm). For vessel wall endothelial cells, no
differences were observed between patients and controls in the day of first colony appearance (e) (9.1 1.1 vs. 7.4 1.2 days,
p¼ 0.30) or the total number of colonies per subject (f) (10.8 3.3 vs. 9.4 2.5, p¼ 0.92). For late outgrowth EOCs, colonies
emerged later from patients compared with controls (m) (10.3 0.8 vs. 7.9 0.5 days, p¼ 0.03) but no difference in colony number
was observed from patients compared with controls (n) (11.8 2.3 vs. 20.9 17.7 colonies, p¼ 0.06). Mean population doubling times
(PDT) between passages 2 and 8 by vessel wall endothelial cells from patients were significantly reduced compared with controls (g)
(mean PDT SEM: 2.3 0.2 vs. 3.4 0.5, p¼ 0.02). Cumulative population doubling levels (CPDL) of vessel wall endothelial cells from
patients were significantly reduced compared with controls (h) (CPDL at passage 8: 18.1 1.4 vs. 23.6 1.4, p¼ 0.03). No significant
difference was observed in mean PDT between passages 2 and 8 by late outgrowth EOCs from patients compared with controls (o)
(2.2 0.2 vs. 2.3 0.2, p¼ 0.89) or in CPDL by late outgrowth EOCs from patients compared with controls (p) (22.3 0.7 vs.
22.2 1.4, p¼ 0.94).
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in the number of circulating EPCs or in the function of
their progeny in patients and controls. It is important
to note that previous reports have deﬁned progenitor
cells in blood based on their co-expression of haemato-
poietic (CD34þ, CD133þ) and vascular (KDRþ) mar-
kers. These studies did not study the function of EOCs
from these putative EPC populations. We isolated,
expanded and characterised EOCs in patients with pre-
mature coronary artery disease and demonstrated that
these cells are similar in number and function to care-
fully matched healthy controls. Our ﬁndings are con-
sistent with a recent report that EOC proliferation was
similar in patients with premature coronary artery dis-
ease and their ﬁrst-degree relatives.27
Endothelial denudation is one of the earliest patho-
physiological features of vascular disease, with persist-
ent endothelial dysfunction responsible for the
progression and clinical manifestations of atherothrom-
bosis.28 The traditional paradigm of vascular repair is
based on the proliferation and migration of existing
mature endothelial cells from the adjacent vasculature.
Our observation that vessel wall endothelial cells have
reduced proliferation, adhesion and migration suggest
that local mechanisms of vascular repair are impaired
in patients who develop premature coronary artery dis-
ease. These ﬁndings are consistent with previous reports
demonstrating endothelial dysfunction in patients with
coronary artery disease29,30 and support a key role for
endothelial dysfunction in the pathogenesis of coronary
artery disease. Whilst the origin of circulating EPCs
remains uncertain, the fact that their progeny are not
dysfunctional suggests that deﬁciencies in the number
and function of circulating EPCs are not central to the
development of premature coronary artery disease.
Why are vessel wall derived endothelial cells but not
EOCs from circulating progenitors dysfunctional? We
postulated that functional diﬀerences might be due to
diﬀerential expression of miRs and therefore transla-
tional repression or degradation of speciﬁc messenger
RNAs and related transcriptional networks. A number
of miRs have been shown to regulate aspects of endo-
thelial function including miR-126,31–38 miR-10 a,34,39
miR27b,40 miR-let7b41 and miR-181b.39,42 We dem-
onstrate that expression of these microRNAs was
reduced in vessel wall endothelial cells, but not in late
outgrowth EOCs in patients with premature coronary
artery disease; hence suggesting broad dysregulation of
endothelial transcriptional networks. Further studies will
explore the pathways through which these microRNAs
regulate vessel wall endothelial cell function.
Our ﬁndings highlight the importance of studying
tissue-appropriate endothelial cells when investigating
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Figure 3. Functional analyses of vessel wall endothelial cells and late outgrowth endothelial outgrowth cells. The potential of vessel
wall derived endothelial cells (ECs) to migrate and undergo wound healing during early passages (passages 2–4) in vitro was signifi-
cantly reduced in patients compared with controls (wound coverage at 24 h: 35.9 8.8% vs. 64.8 12.7%, p¼ 0.04, n¼ 16 for both)
((a) to (c); 10 magnification). Conversely, wound healing by late outgrowth endothelial outgrowth cells (EOCs) was similar in
patients and controls (wound coverage at 24 h: 62.2 8.2% vs. 56.3 8.0%, p¼ 0.60, n¼ 16 for both) ((e) to (g); 10 magnification).
Wound healing assays are representative phase contrast images of endothelial cells ((a) and (b)) and EOCs ((e) and (f)) from a patient
with premature coronary artery disease at passage 2. Similarly, cell adhesion by vessel wall endothelial cells was significantly reduced in
patients compared with controls (adherent cells per well SEM: 31.5 5.4 vs. 53.3 6.6, p¼ 0.02, n¼ 16 for both) (d), whereas no
differences were observed in adhesion by late outgrowth EOCs in patients and controls (adherent cells per well: 52.0 7.1 vs.
57.3 11.2, p¼ 0.83, n¼ 16 for both) (h).
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the pathogenesis of disease.13,16 To date, studies have
been challenging in humans due to the challenges asso-
ciated with accessing vascular endothelial cells.
However, we report novel methods for the expansion
and maintenance in culture of vessel wall endothelial
cells from both patients and healthy controls. This
method was adapted from an endothelial biopsy proto-
col where cells were immediately ﬁxed for quantitative
immunoﬂuorescence.43,44 This development permitted
the ﬁrst functional and phenotypic analyses of human
vessel wall endothelial cells maintained long-term in
culture, and a direct comparison of these cells with
circulating EPCs and EOCs from the same patients.
Our study has a number of strengths. First, we iden-
tiﬁed well-characterised patients and matched healthy
controls, and all participants underwent a gold stand-
ard assessment of vascular function. Second, we have
carefully quantiﬁed multiple putative circulating EPC
populations, and comprehensively characterised the
function of EOCs. Third, we developed novel methods
to culture vessel wall endothelial cells from patients to
understand the role of local endothelial cells in vascular
repair. However, there are also some limitations to con-
sider. We have evaluated EPCs at a single time point in
patients with stable disease and it is not possible to
determine whether patients have deﬁciencies in EPC
mobilisation at times of acute vascular injury.
However, our previous studies suggest that phenotypic
EPCs are not mobilised in the context of local vascular
injury during angioplasty or stent implantation6 or sys-
temic injury following acute systemic inﬂammation.45
Our patient population was young and selected to
have few traditional risk factors for coronary artery
disease. Whilst this avoids potential confounding due
to conditions such as diabetes mellitus or cigarette
smoking that may inﬂuence EPC function, our obser-
vations may not be generalisable to the broader popu-
lation of patients with coronary artery disease.
In conclusion, impaired proliferation, adhesion,
migration and reduced microRNA expression of local
vessel wall endothelial cells, rather than circulating
EPCs, was associated with endothelial dysfunction
and premature coronary artery disease. Future studies
of vessel wall endothelial cells are likely to advance our
understanding of the mechanisms of premature coron-
ary artery disease and may lead to novel approaches to
enhance vascular repair.
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